MediciNova

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.

LA JOLLA, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's research collaborator Masatsune Ogura, M.D., Ph.D., Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, is presenting results and findings of a study that investigated the mechanism by which MN-001 (tipelukast) alters triglyceride (TG) metabolism in hepatocytes at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) to be held online from November 12th to 15t h. In this study, HepG2 cells derived from human hepatocellular carcinoma samples were incubated for 48 hours with arachidonic acid (AA), LXR agonist T0901317, and MN-001 (tipelukast) each alone or in various combinations. The amount of TG synthesis in the HepG2 cells was calculated by extracting lipids from the HepG2 cells before and after treatment. As a result, it was found that MN-001 had an inhibitory effect on TG synthesis in HepG2 cells.

MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LA JOLLA, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Grazia Ambrosini, PhD, an associate research scientist at Columbia University Vagelos College of Physicians and Surgeons, presented data regarding MN-166 (ibudilast) in a uveal melanoma (UM) model study at the 10th Annual CURE OM Global Science Meeting held online as a part of the Society for Melanoma Research International Congress on October 28, 2021.

MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting

LA JOLLA, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova's collaborator, Dr. Justin Lathia, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, will present new data regarding MN-166 (ibudilast) from a glioblastoma animal model study at the 26th Annual Meeting of the Society for Neuro-Oncology (SNO) to be held November 18 - 21, 2021 in Boston.

MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology

LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “MN-001 (tipelukast) reduces triglycerides levels in hepatocytes by down-regulating fatty acid translocase/CD36 expression" has been selected for presentation at the 19th International Symposium on Atherosclerosis (ISA2021) to be held October 24 - 27, 2021 in a hybrid format both online and onsite at the Kyoto International Conference Center in Kyoto, Japan.

MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)

LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference which will be held from September 9 - 15, 2021.  Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Morgan Stanley.

MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

LA JOLLA, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “Improvement of Intracellular Lipid Metabolism by Tipelukast in the Pathogenesis of NASH/NAFLD" has been selected for poster presentation at The Liver Meeting® 2021, the annual meeting of the American Association for the Study of Liver Diseases (AASLD) to be held November 12 - 15, 2021. MediciNova's research collaborator, Dr. Masatsune Ogura, Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, will present the results of the study. Presentation details will be disseminated as they become available.

MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

LA JOLLA, Calif., Aug. 30, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding MediciNova's ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) has been accepted for presentation at the 32nd International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) to be held virtually on December 7 - 10, 2021.

MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND

Initiated preclinical animal studies for MN-166 as a treatment for chlorine gas-induced induced lung disease under partnership with BARDA

MediciNova Reports Second Quarter 2021 Financial Results and Business Update

LA JOLLA, Calif., July 06, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-166 (ibudilast) for the treatment of ophthalmic disease.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease

LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July 13, 2021 at 4:30 pm ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann.

MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

MediciNova Inc (NASDAQ: MNOV) will conduct a mouse study to investigate the efficacy of MN-166 (ibudilast) in a murine model of chlorine-induced lung injury and lethality.  After mice are exposed to chlorine gas and treated with MN-166 (ibudilast) or control, the study will evaluate survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histopathology.

MediciNova To Test Ibudilast In BARDA's Validated Mouse Model Of Chlorine-Induced Pulmonary Injury

LA JOLLA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it will conduct a mouse study to investigate the efficacy of MN-166 (ibudilast) in a murine model of chlorine-induced lung injury and lethality. After mice are exposed to chlorine gas and treated with MN-166 (ibudilast) or control, the study will evaluate survival, clinical outcomes, body weights, lung weights, and upper respiratory tract histopathology.

MediciNova to Conduct Mouse Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Aditxt Inc

Sphere 3D

Vinco Ventures

Globalstar

Gran Tierra Energy

Luokung Technology Corp

New Gold

Pieris Pharma

Qudian

Transocean

Tellurian

US Well Services

Uxin Ltd - ADR

Xeris Biopharma Holdings

These penny stocks are trending right now, here's why The post Best Penny Stocks to Buy Right Now? 15 To Watch In July appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 15 To Watch In July

Adial Pharmaceuticals Inc

Intec Parent

OPKO Health

vTv Therapeutics

Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Top 10 Biotech Penny Stocks to Watch in July 2021

MediciNov Inc (NASDAQ: MNOV) sees a trading volume of 18.5 million shares after Zacks Small Cap Research increased the stock price target to $28 from $26.5 earlier. The research notes positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) published in Translational Psychiatry.

MediciNov Sees Volume After Zacks Research Raises Price Target To $28

Looking for the top penny stocks on Reddit? Check these 10 out The post Hot Reddit Penny Stocks to Buy?

Hot Reddit Penny Stocks to Buy? 10 That You Should Know About

The stock price of MediciNova, Inc. (NASDAQ: MNOV) increased by over 30% during intraday trading. This is why it happened.

MNOV Stock Price Increases Over 30%: Why It Happened

LA JOLLA, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that positive results from a Phase 2 trial of MN-166 (ibudilast) in alcohol use disorder (AUD) were published in Nature's Translational Psychiatry.

MediciNova Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature's Translational Psychiatry Journal

LA JOLLA, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and Geoffrey O'Brien, JD/MBA, Vice President and Executive Officer, will participate in a fireside chat hosted by Maxim Group LLC Analyst Jason McCarthy, Ph.D., Senior Managing Director, Biotechnology, on Wednesday, June 23, 2021 at 1:00 pm ET.   Investors may request access to this event through Maxim Group LLC.

MediciNova to Participate in Maxim Group LLC Fireside Chat

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced it has initiated a sheep study to investigate MN-166 (ibudilast) in an ovine model of chlorine-induced acute lung injury. Following treatment of the sheep with MN-166 (ibudilast) or control, the study will evaluate pulmonary function, lung injury and edema formation, cardiopulmonary hemodynamics, and systemic vascular permeability.

MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

- Completed $20M private placement financing with 3D Investment Partners -

MediciNova Reports First Quarter 2021 Financial Results and Business Update

The stock price of MediciNova, Inc. (NASDAQ: MNOV) increased 4.71% (from $4.25 to $4.45) pre-market. This is why it happened.

MNOV Stock: 4.71% Increase (From $4.25 To $4.45) Pre-Market Explanation

LA JOLLA, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received a Notice of Intention to Grant from the European Patent Office for a pending patent application which covers the combination of MN-166 (ibudilast) and riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

MediciNova is a development phase biotech with several highly attractive development candidates. MediciNova's plans for developing these candidates are a bit of a riddle.

The MediciNova Riddle: Worth Unravelling

LA JOLLA, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it has received two milestone payments under MediciNova's assignment agreement with Genzyme Corporation, a subsidiary of Sanofi. The milestone payments, which total $4 million, are a result of the successful achievement of two clinical development milestones for a gene therapy product based on AAV (adeno-associated virus) vector technology that is covered under the assignment agreement.

News for MediciNova Stock (MNOV)